MA29925B1 - Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds - Google Patents
Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgdsInfo
- Publication number
- MA29925B1 MA29925B1 MA30891A MA30891A MA29925B1 MA 29925 B1 MA29925 B1 MA 29925B1 MA 30891 A MA30891 A MA 30891A MA 30891 A MA30891 A MA 30891A MA 29925 B1 MA29925 B1 MA 29925B1
- Authority
- MA
- Morocco
- Prior art keywords
- amide compounds
- compound
- pgds inhibitors
- pyrimidine amide
- pyrimidine
- Prior art date
Links
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 title 1
- 101710145576 Prostaglandin-H2 D-isomerase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- FUXJMHXHGDAHPD-UHFFFAOYSA-N pyrimidine-2-carboxamide Chemical class NC(=O)C1=NC=CC=N1 FUXJMHXHGDAHPD-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 201000009961 allergic asthma Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un composé de formule (I) : dans lequel R1, R2, R3 et L1 sont comme présentement définis, une composition pharmaceutique comprenant le composé, et l'utilisation du composé pour traiter des troubles allergiques et/ou inflammatoires, en particulier des troubles tels que la rhinite allergique, l'asthme et/ou la bronchopneumopathie chronique obstructive (COPD).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72357005P | 2005-10-04 | 2005-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29925B1 true MA29925B1 (fr) | 2008-11-03 |
Family
ID=37635758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30891A MA29925B1 (fr) | 2005-10-04 | 2008-05-02 | Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8202863B2 (fr) |
| EP (1) | EP1937652B1 (fr) |
| JP (1) | JP5452925B2 (fr) |
| KR (1) | KR101457966B1 (fr) |
| CN (2) | CN101538246B (fr) |
| AR (1) | AR056871A1 (fr) |
| AU (1) | AU2006299428B2 (fr) |
| BR (1) | BRPI0616815A2 (fr) |
| CA (1) | CA2624749C (fr) |
| CR (1) | CR9832A (fr) |
| DO (1) | DOP2006000210A (fr) |
| EC (1) | ECSP088335A (fr) |
| ES (1) | ES2514471T3 (fr) |
| IL (1) | IL190411A (fr) |
| MA (1) | MA29925B1 (fr) |
| MY (1) | MY151172A (fr) |
| NO (1) | NO20082000L (fr) |
| NZ (1) | NZ567208A (fr) |
| PE (2) | PE20070589A1 (fr) |
| RU (1) | RU2420519C2 (fr) |
| SG (1) | SG166121A1 (fr) |
| TN (1) | TNSN08104A1 (fr) |
| TW (1) | TWI415839B (fr) |
| UA (1) | UA93213C2 (fr) |
| UY (1) | UY29840A1 (fr) |
| WO (1) | WO2007041634A1 (fr) |
| ZA (1) | ZA200802222B (fr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007031829A2 (fr) * | 2005-09-15 | 2007-03-22 | Orchid Research Laboratories Limited | Nouveaux pyrimidine carboxamides |
| PE20070589A1 (es) | 2005-10-04 | 2007-06-22 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| KR20080109918A (ko) | 2006-04-11 | 2008-12-17 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물 |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| WO2008104869A1 (fr) | 2007-02-26 | 2008-09-04 | Pfizer Products Inc. | Composés hétérocycliques utiles dans le traitement de maladies et de conditions |
| EP2182809B1 (fr) | 2007-08-27 | 2018-01-17 | Dart Neuroscience (Cayman) Ltd | Composés isoxazole thérapeutiques |
| EP2212290B1 (fr) | 2007-10-11 | 2014-12-03 | Vertex Pharmaceuticals Incorporated | Aryl amides utiles en tant qu'inhibiteurs de canaux sodiques sensibles au voltage |
| JP5555169B2 (ja) * | 2007-10-11 | 2014-07-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド |
| NZ584474A (en) | 2007-10-11 | 2012-06-29 | Vertex Pharma | Amides useful as inhibitors of voltage-gated sodium channels |
| JP2011503072A (ja) * | 2007-11-13 | 2011-01-27 | レノビス， インコーポレイテッド | イオンチャネルのリガンドとしてのアミド誘導体ならびにそれを使用する薬学的組成物および方法 |
| CA2711399C (fr) * | 2008-02-06 | 2016-10-11 | Banyu Pharmaceutical Co., Ltd. | Derive de sulfonylpiperazine substitue en position 3 |
| EP2286221A4 (fr) * | 2008-05-13 | 2011-07-06 | Cayman Chem Co | Procédés d'évaluation de la capacité de composés ou d'agents à déplacer de puissants ligands de la prostaglandine d synthase hématopoïétique |
| TW201010997A (en) | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| US20110306597A1 (en) | 2008-06-18 | 2011-12-15 | James Michael Crawforth | Nicotinamide Derivatives |
| KR20130105914A (ko) | 2008-09-22 | 2013-09-26 | 카이맨 케미칼 컴파니 인코포레이티드 | Ｈ-ｐｇｄｓ 억제제로서 다중헤테로아릴 화합물 및 프로스타글란딘 ｄ2 매개된 질병의 치료를 위한 그의 용도 |
| KR101252335B1 (ko) | 2009-07-16 | 2013-04-08 | (주)아모레퍼시픽 | 피부 노화 방지용 조성물 |
| WO2010056044A2 (fr) * | 2008-11-11 | 2010-05-20 | (주)아모레퍼시픽 | Nouveau composé faisant fonction d'antagoniste du récepteur vanilloïde, isomère ou sel pharmaceutiquement acceptable dudit composé, et composition pharmaceutique le contenant |
| KR101367057B1 (ko) | 2009-03-17 | 2014-02-25 | (주)아모레퍼시픽 | 피부 자극 완화용 조성물 |
| MX2011009423A (es) | 2009-03-09 | 2011-09-28 | Taiho Pharmaceutical Co Ltd | Compuesto de piperazina capaz de inhibir prostaglandina d sintasa. |
| CN107875155A (zh) | 2009-10-08 | 2018-04-06 | 赛诺菲 | 苯基噁二唑衍生物在制备治疗变应性或炎性疾病的药物中的用途 |
| KR101723707B1 (ko) * | 2010-01-22 | 2017-04-05 | 다이호야쿠힌고교 가부시키가이샤 | Ｐｇｄｓ 저해 작용을 갖는 피페라진 화합물 |
| US9320723B2 (en) * | 2010-05-03 | 2016-04-26 | University Of Rochester | Methods of treating thyroid eye disease |
| EP2576536B1 (fr) * | 2010-06-01 | 2016-09-14 | The University of Queensland | Inhibiteurs de la prostaglandine d2 synthase hématopoïétique |
| CA2810489A1 (fr) | 2010-09-07 | 2012-03-15 | Yoshihiro Urade | Composes de piperidine inhibiteurs de la prostaglandine d synthase |
| KR101271223B1 (ko) | 2011-01-27 | 2013-06-07 | 한국과학기술연구원 | 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제 |
| AU2013207510A1 (en) * | 2012-01-06 | 2014-07-31 | The Regents Of The University Of California | Compositions, methods of use, and methods of treatment |
| CN103626752B (zh) * | 2012-08-24 | 2015-08-12 | 广东东阳光药业有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| AU2016370779B2 (en) | 2015-12-17 | 2019-07-25 | Astex Therapeutics Limited | Quinoline-3-carboxamides as H-PGDS inhibitors |
| EP3429588B1 (fr) * | 2016-03-14 | 2024-09-18 | Emory University | Dérivés amide-sulfamide, compositions et utilisations associées à l'inhibition de cxcr4 |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| US11149035B2 (en) | 2017-06-13 | 2021-10-19 | Glaxosmithkline Intellectual Property Dfvelopment Limited | Chemical compounds as H—PGDS inhibitors |
| US11357759B2 (en) | 2017-10-29 | 2022-06-14 | China Medical University | Composition including ADAM9 inhibitor and the use thereof |
| US20210139507A1 (en) | 2017-12-13 | 2021-05-13 | Glaxosmithkline Intellectual Property Development Limited | Fused pyridines which act as inhibitors of h pgds |
| CA3093050A1 (fr) * | 2018-03-23 | 2019-09-26 | Step Pharma S.A.S. | Derives d'aminopyrimidine utilises comme inhibiteurs de ctps1 |
| JP2022506850A (ja) | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
| AR122072A1 (es) * | 2020-05-13 | 2022-08-10 | Chdi Foundation Inc | Moduladores htt para tratar la enfermedad de huntington |
| US20230339937A1 (en) | 2020-06-19 | 2023-10-26 | Sato Pharmaceutical Co., Ltd. | Condensed ring compounds that inhibit h-pgds |
| CN116601131A (zh) * | 2020-10-23 | 2023-08-15 | 林伯士克洛索有限公司 | Ctps1抑制剂及其用途 |
| CN113004208A (zh) * | 2021-03-08 | 2021-06-22 | 沈阳药科大学 | 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用 |
| CN118510769A (zh) | 2021-11-17 | 2024-08-16 | Chdi基金会股份有限公司 | 用于治疗亨廷顿病的htt调节剂 |
| CA3240926A1 (fr) | 2021-12-17 | 2023-06-22 | Sato Pharmaceutical Co., Ltd. | Derive d'azaindole inhibant h-pgds |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2934543A1 (de) * | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| JPH03112985A (ja) * | 1989-09-28 | 1991-05-14 | Morishita Pharmaceut Co Ltd | Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体 |
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| JP2000226372A (ja) * | 1999-02-01 | 2000-08-15 | Nippon Soda Co Ltd | アミド化合物、その製造方法及び農園芸用殺虫剤 |
| JP2002003370A (ja) * | 1999-09-20 | 2002-01-09 | Takeda Chem Ind Ltd | メラニン凝集ホルモン拮抗剤 |
| AU7315700A (en) * | 1999-09-20 | 2001-04-24 | Takeda Chemical Industries Ltd. | Melanin concentrating hormone antagonist |
| MY138097A (en) * | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| JP2003112985A (ja) | 2001-10-01 | 2003-04-18 | Nre Happiness Kk | 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット |
| WO2004011430A1 (fr) * | 2002-07-25 | 2004-02-05 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteur des canaux sodium |
| US7541477B2 (en) * | 2002-07-30 | 2009-06-02 | Banyu Pharmaceutical Co., Ltd. | Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| EP1606289B1 (fr) * | 2003-02-14 | 2009-12-02 | Glaxo Group Limited | Derives de carboxamide |
| DK1471057T3 (da) * | 2003-04-25 | 2006-05-15 | Actimis Pharmaceuticals Inc | Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 |
| EP1685109A2 (fr) | 2003-10-07 | 2006-08-02 | Renovis, Inc. | Composes d'amides utilises en tant que ligands de canaux ioniques et utilisations correspondantes |
| JP2007518816A (ja) * | 2004-01-23 | 2007-07-12 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用 |
| PE20070589A1 (es) | 2005-10-04 | 2007-06-22 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
-
2006
- 2006-10-03 PE PE2006001202A patent/PE20070589A1/es not_active Application Discontinuation
- 2006-10-03 DO DO2006000210A patent/DOP2006000210A/es unknown
- 2006-10-03 PE PE2010000532A patent/PE20110118A1/es not_active Application Discontinuation
- 2006-10-03 AR ARP060104348A patent/AR056871A1/es unknown
- 2006-10-04 MY MYPI20080754 patent/MY151172A/en unknown
- 2006-10-04 CA CA2624749A patent/CA2624749C/fr not_active Expired - Fee Related
- 2006-10-04 NZ NZ567208A patent/NZ567208A/en not_active IP Right Cessation
- 2006-10-04 CN CN200910138053.9A patent/CN101538246B/zh active Active
- 2006-10-04 CN CNA2006800365786A patent/CN101282943A/zh active Pending
- 2006-10-04 TW TW095136806A patent/TWI415839B/zh not_active IP Right Cessation
- 2006-10-04 WO PCT/US2006/038841 patent/WO2007041634A1/fr not_active Ceased
- 2006-10-04 AU AU2006299428A patent/AU2006299428B2/en not_active Ceased
- 2006-10-04 ES ES06816247.8T patent/ES2514471T3/es active Active
- 2006-10-04 EP EP06816247.8A patent/EP1937652B1/fr active Active
- 2006-10-04 JP JP2008534664A patent/JP5452925B2/ja active Active
- 2006-10-04 UA UAA200805322A patent/UA93213C2/ru unknown
- 2006-10-04 UY UY29840A patent/UY29840A1/es unknown
- 2006-10-04 BR BRPI0616815-9A patent/BRPI0616815A2/pt not_active IP Right Cessation
- 2006-10-04 KR KR1020087008306A patent/KR101457966B1/ko not_active Expired - Fee Related
- 2006-10-04 SG SG201007241-1A patent/SG166121A1/en unknown
- 2006-10-04 RU RU2008117170/04A patent/RU2420519C2/ru not_active IP Right Cessation
-
2008
- 2008-03-07 TN TNP2008000104A patent/TNSN08104A1/en unknown
- 2008-03-10 ZA ZA200802222A patent/ZA200802222B/xx unknown
- 2008-03-24 IL IL190411A patent/IL190411A/en not_active IP Right Cessation
- 2008-03-26 CR CR9832A patent/CR9832A/es not_active Application Discontinuation
- 2008-04-02 EC EC2008008335A patent/ECSP088335A/es unknown
- 2008-04-04 US US12/062,641 patent/US8202863B2/en active Active
- 2008-04-28 NO NO20082000A patent/NO20082000L/no not_active Application Discontinuation
- 2008-05-02 MA MA30891A patent/MA29925B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29925B1 (fr) | Composes d'amide de pyrimidine en tant qu'inhibiteurs de pgds | |
| MA31326B1 (fr) | Pyrimidine-hydrazides en tant qu'inhibiteurs de pgds | |
| TNSN04151A1 (fr) | Derives de nicotinamide utiles comme inhibiteurs de pde4 | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| NO20090910L (no) | Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister | |
| MA35285B1 (fr) | Indazoles | |
| NO20084005L (no) | Aminderivater | |
| WO2005121130A3 (fr) | Composes pour le traitement de troubles inflammatoires | |
| PL357555A1 (en) | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | |
| DE602006013493D1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2-antagonisten | |
| MA32615B1 (fr) | Inhibiteurs de cmet | |
| NO20053794L (no) | N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine. | |
| MA33725B1 (fr) | Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| WO2007011833A3 (fr) | Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer | |
| WO2004033431A3 (fr) | Hydroxypyrazoles et methodes prophylactiques ou de traitement de troubles lies au metabolisme | |
| EP1423111A4 (fr) | Composes de liaison au recepteur nucleaire fxr nr1h4 | |
| EA200701361A1 (ru) | Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ | |
| MA32798B1 (fr) | Acides naphtylacétiques | |
| WO2007146349A3 (fr) | Antagonistes du récepteur du cgrp | |
| MXPA05012329A (es) | Compuestos utiles para el tratamiento de enfermedades. | |
| MA29267B1 (fr) | Cyclopropyl-(2, 3-dimethylbenzyl)amides d'acide 7-{4-[2-(2,6-dichloro-4-methylphenoxy)-ethoxy] phenyl}-3, 9-diazabicyclo [3.3.1] non-6-ene-6-carboxylique comme inhibiteurs de la renine pour le traitement de l'hypertension. | |
| WO2006002434A3 (fr) | Nouveaux indazole carboxamides et leur utilisation | |
| WO2006055434A3 (fr) | Inhibiteurs de la beta-secretase formes d'amines tertiaires macrocycliques pour le traitement de la maladie d'alzheimer | |
| WO2005090287A3 (fr) | Composes convenant pour le traitement de maladies |